{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:30:30Z","timestamp":1787499030105,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>\n                      Multidrug-resistant bacterial infections limit available therapeutic options. Doxycycline is an old antibiotic from the tetracycline class that exhibits a wide antibacterial action, including Gram-negative bacteria (GNB), and could be an alternative for the treatment of multidrug-resistant (MDR)\n                      <jats:italic toggle=\"yes\">Enterobacteriaceae<\/jats:italic>\n                      . The study aimed to systematically identify, evaluate, and summarize the results of studies related to outcomes of treatments for MDR-GNB infections in patients treated with doxycycline.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This review was conducted in four databases during weeks 41\u201352 of 2022: PubMed, Medline, Scopus, and Web of Science, from the earliest year available on each database to December 2022. Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines were followed in conducting this study, and PICO was used for the research question of this review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>This scoping review found 8 retrospective studies that included 59 patients. Of these, 69% were treated for ventilator-associated pneumonia (VAP), 27% for urinary tract infections, 2% for bloodstream infections, and 2% for wound infections, both of which were associated with VAP. The usual dosage of doxycycline was 100 mg intravenously or orally. Clinical and microbiologic improvements were achieved in 81.3% and 87% of all patients, respectively. The mortality rate was 17.3% and was exclusively due to VAP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Doxycycline showed promising results in this review; however, randomized clinical trials or prospective cohorts are recommended to demonstrate the efficacy of doxycycline in the treatment of MDR infections with GNB.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jgid.jgid_34_23","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T11:09:43Z","timestamp":1693307383000},"page":"95-100","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Doxycycline for Multidrug-Resistant Gram-Negative Bacterial Infection Treatment: A Scoping Review"],"prefix":"10.4103","volume":"15","author":[{"given":"Viviane","family":"de Macedo","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Hospital Infection Control and Epidemiology Center, Santa Casa de Curitiba, Curitiba, Paran\u00e1, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno Pandolfo","family":"Meneghete","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Medicine School, Positive University, Curitiba, Paran\u00e1, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Cassiano","family":"Koaski","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Medicine School, Positive University, Curitiba, Paran\u00e1, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari\u00e1dne Sousa","family":"Albuquerque","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Infection Control and Epidemiology Center, Santa Casa de Curitiba, Curitiba, Paran\u00e1, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Millan","family":"Fachi","sequence":"additional","affiliation":[{"name":"Value Management Office, Hospital Pequeno Pr\u00edncipe, Curitiba, Paran\u00e1, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,8,11]]},"reference":[{"key":"R1-20240828","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3390\/molecules23040795","article-title":"Antibiotic use in agriculture and its consequential resistance in environmental sources:Potential Public health implications","volume":"23","author":"Manyi-Loh","year":"2018","journal-title":"Molecules"},{"key":"R2-20240828","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1179\/2047773215Y.0000000030","article-title":"Antimicrobial resistance:A global multifaceted phenomenon","volume":"109","author":"Prestinaci","year":"2015","journal-title":"Pathog Glob Health"},{"key":"R3-20240828","first-page":"277","article-title":"The antibiotic resistance crisis:Part 1:Causes and threats","volume":"40","author":"Ventola","year":"2015","journal-title":"P T"},{"key":"R4-20240828","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1476-5381.2011.01250.x","article-title":"Novel classes of antibiotics or more of the same?","volume":"163","author":"Coates","year":"2011","journal-title":"Br J Pharmacol"},{"key":"R5-20240828","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fpubh.2019.00151","article-title":"The \u201cold\u201dand the \u201cnew\u201d antibiotics for MDR gram-negative pathogens:For whom, when, and how","volume":"7","author":"Karaiskos","year":"2019","journal-title":"Front Public Health"},{"key":"R6-20240828","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jac\/dkl224","article-title":"Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines","volume":"58","author":"Agwuh","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"R7-20240828","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fmicb.2019.00080","article-title":"Infections caused by carbapenem-resistant Enterobacteriaceae:An update on therapeutic options","volume":"10","author":"Sheu","year":"2019","journal-title":"Front Microbiol"},{"key":"R8-20240828","doi-asserted-by":"crossref","first-page":"31964","DOI":"10.1038\/srep31964","article-title":"The role of doxycycline in the therapy of multidrug-resistant E. coli \u2013An in vitro study","volume":"6","author":"Lai","year":"2016","journal-title":"Sci Rep"},{"key":"R10-20240828","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ijantimicag.2014.12.031","article-title":"Tetracyclines for multidrug-resistant Acinetobacter baumannii infections","volume":"45","author":"Falagas","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"R11-20240828","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1007\/s00134-003-1811-2","article-title":"Tetracyclines for treating multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"29","author":"Wood","year":"2003","journal-title":"Intensive Care Med"},{"key":"R12-20240828","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1345\/aph.1H353","article-title":"Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit","volume":"40","author":"Holloway","year":"2006","journal-title":"Ann Pharmacother"},{"key":"R13-20240828","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/0885066610377975","article-title":"Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"25","author":"Chan","year":"2010","journal-title":"J Intensive Care Med"},{"key":"R14-20240828","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.clinthera.2012.05.002","article-title":"Treatment and clinical outcomes of urinary tract infections caused by KPC-producing Enterobacteriaceae in a retrospective cohort","volume":"34","author":"Alexander","year":"2012","journal-title":"Clin Ther"},{"key":"R15-20240828","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1016\/j.transproceed.2013.07.064","article-title":"Infections with blaKPC-2-producing Klebsiella pneumoniae in renal transplant patients:A retrospective study","volume":"45","author":"Cicora","year":"2013","journal-title":"Transplant Proc"},{"key":"R16-20240828","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1128\/AAC.02445-13","article-title":"Epidemiology and clinical outcomes of patients with carbapenem-resistant Klebsiella pneumoniae bacteriuria","volume":"58","author":"Qureshi","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R17-20240828","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ijantimicag.2014.12.019","article-title":"Persistent extended-spectrum b-lactamase-positive Escherichia coli chronic prostatitis successfully treated with a combination of fosfomycin and doxycycline","volume":"45","author":"Cunha","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"R18-20240828","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1177\/0897190016642362","article-title":"Successful doxycycline therapy in a patient with Escherichia coli and multidrug-resistant Klebsiella pneumoniae urinary tract infection","volume":"30","author":"White","year":"2017","journal-title":"J Pharm Pract"},{"key":"R19-20240828","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/jac\/45.4.493","article-title":"Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia","volume":"45","author":"Rodr\u00edguez-Hern\u00e1ndez","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"R20-20240828","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1046\/j.1469-0691.2000.00058-2.x","article-title":"Pharmacodynamics of doxycycline","volume":"6","author":"Cunha","year":"2000","journal-title":"Clin Microbiol Infect"},{"key":"R21-20240828","first-page":"471","article-title":"Safety and efficacy review of doxycycline","volume":"1","author":"Holmes","year":"2009","journal-title":"Clin Med Ther"},{"key":"R22-20240828","doi-asserted-by":"crossref","first-page":"575","DOI":"10.5694\/j.1326-5377.1979.tb127087.x","article-title":"Pharmacokinetics and tolerability of a single oral 600-mg dose of doxycycline","volume":"1","author":"Marlin","year":"1979","journal-title":"Med J Aust"},{"key":"R23-20240828","first-page":"276","article-title":"Sputum and plasma doxycycline concentrations after a single oral 600 mg doxycycline dose in patients with chronic bronchitis","volume":"62","author":"Marlin","year":"1981","journal-title":"Eur J Respir Dis"},{"key":"R24-20240828","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1378\/chest.78.2.304","article-title":"Tissue levels of doxycycline in the human lung and pleura","volume":"78","author":"Thadepalli","year":"1980","journal-title":"Chest"}],"container-title":["Journal of Global Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jgid.jgid_34_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:26:44Z","timestamp":1786724804000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jgid.jgid_34_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/jgid.jgid_34_23","relation":{},"ISSN":["0974-777X","0974-8245"],"issn-type":[{"value":"0974-777X","type":"print"},{"value":"0974-8245","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"2023-02-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}